Articles By Anuja Singh

Will Merck’s CAPVAXIVE® 21-Valent Vaccine Set a New Benchmark in Pediatric Pneumococcal Protection After…

Key Highlights Promising Phase 3 Data from STRIDE-13 TrialMerck announced that CAPVAXIVE demonstrated robust immunogenicity and safety in…

ByByAnuja SinghSep 11, 2025
Could Sanofi’s One-Time Gene Therapy SAR402663 Transform Treatment for Neovascular Age-Related Macular Degeneration?

Key Highlights A Major Step Forward in Retinal Disease InnovationThe FDA’s Fast Track designation underscores the urgent need…

ByByAnuja SinghSep 11, 2025
Is Lilly’s “TuneLab” the Breakthrough AI Collaboration Model Biotech Startups Have Been Waiting For?

Key Highlights A bold move: Lilly democratizes AI for biotechEli Lilly has launched TuneLab, a novel AI platform…

ByByAnuja SinghSep 10, 2025
Can Gilead’s Twice-Yearly Yeytuo® (Lenacapavir) Redefine HIV Prevention Across Europe With Zero Infections in…

Key Insights: A Historic European Approval That Expands Prevention Choices The European Commission granted marketing authorization for Gilead’s…

ByByAnuja SinghSep 10, 2025
Can Amgen and Kyowa Kirin’s Rocatinlimab Redefine Atopic Dermatitis Care With Long-Term Safety and…

Key Insights: Breakthrough Data From ASCEND Long-Term Extension Amgen and Kyowa Kirin released top-line results from the global…

ByByAnuja SinghSep 10, 2025
Lilly’s Jaypirca Shows Strong Phase 3 Results in Untreated CLL/SLL

Eli Lilly and Company (NYSE: LLY) announced positive topline results from the Phase 3 BRUIN CLL-313 trial evaluating…

ByByAnuja SinghSep 9, 2025
Image Not Found
Will Merck’s CAPVAXIVE® 21-Valent Vaccine Set a New Benchmark in Pediatric Pneumococcal Protection After…

Key Highlights Promising Phase 3 Data from STRIDE-13 TrialMerck announced that CAPVAXIVE demonstrated robust immunogenicity and safety in…

ByByAnuja SinghSep 11, 2025
Could Sanofi’s One-Time Gene Therapy SAR402663 Transform Treatment for Neovascular Age-Related Macular Degeneration?

Key Highlights A Major Step Forward in Retinal Disease InnovationThe FDA’s Fast Track designation underscores the urgent need…

ByByAnuja SinghSep 11, 2025
Is Lilly’s “TuneLab” the Breakthrough AI Collaboration Model Biotech Startups Have Been Waiting For?

Key Highlights A bold move: Lilly democratizes AI for biotechEli Lilly has launched TuneLab, a novel AI platform…

ByByAnuja SinghSep 10, 2025
Can Gilead’s Twice-Yearly Yeytuo® (Lenacapavir) Redefine HIV Prevention Across Europe With Zero Infections in…

Key Insights: A Historic European Approval That Expands Prevention Choices The European Commission granted marketing authorization for Gilead’s…

ByByAnuja SinghSep 10, 2025
Can Amgen and Kyowa Kirin’s Rocatinlimab Redefine Atopic Dermatitis Care With Long-Term Safety and…

Key Insights: Breakthrough Data From ASCEND Long-Term Extension Amgen and Kyowa Kirin released top-line results from the global…

ByByAnuja SinghSep 10, 2025
Lilly’s Jaypirca Shows Strong Phase 3 Results in Untreated CLL/SLL

Eli Lilly and Company (NYSE: LLY) announced positive topline results from the Phase 3 BRUIN CLL-313 trial evaluating…

ByByAnuja SinghSep 9, 2025
Scroll to Top